Merlin sumoylation is required for its tumor suppressor activity

Oncogene

Volumn 33, Issue 41, 2014, Pages 4893-4903

  Qi, Q ^a   Liu, X ^a   Brat, D J ^a   Ye, K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; merlin; NF2; sumoylation; tumor suppressor

Indexed keywords

ARGININE; MERLIN; MUTANT PROTEIN; P21 ACTIVATED KINASE 2; PROTEIN KINASE B; SUMO 1 PROTEIN; LYSINE; P21 ACTIVATED KINASE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL DENSITY; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; CYTOSKELETON; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NEURILEMOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; RAT; SEQUENCE ANALYSIS; SUMOYLATION; TUMOR MODEL; TUMOR XENOGRAFT; 3T3 CELL LINE; ANIMAL; BINDING SITE; CELL LINE; GENETICS; HELA CELL LINE; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION; PROTEIN TRANSPORT; TUMOR SUPPRESSOR GENE;

AMINO ACID SUBSTITUTION; ANIMALS; ARGININE; BINDING SITES; CELL LINE; CYTOPLASM; GENES, TUMOR SUPPRESSOR; HELA CELLS; HUMANS; LYSINE; MCF-7 CELLS; MICE; NEUROFIBROMIN 2; NIH 3T3 CELLS; P21-ACTIVATED KINASES; PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; SUMOYLATION;

EID: 84921728604     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.438     Document Type: Article

References (63)

1. Evans GR, Lloyd SK, Ramsden RT. Neurofibromatosis type 2. Adv Oto-rhino-laryngol 2011; 70: 91-98.
2. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363: 515-521.
3. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 75: 826.
4. Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 1994; 126: 391-401.
5. Chishti AH, Kim AC, Marfatia SM, Lutchman M, Hanspal M, Jindal H et al. The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci 1998; 23: 281-282.
6. Hamada K, Shimizu T, Matsui T, Tsukita S, Hakoshima T. Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain. EMBO J 2000; 19: 4449-4462.
7. Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 2005; 171: 361-371.
8. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 2001; 1: 63-72.
9. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 2009; 29: 4250-4261.
10. Lopez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009; 29: 4235-4249.
11. Cole BK, Curto M, Chan AW, McClatchey AI. Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol 2008; 28: 1274-1284.
12. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signalregulated kinase pathway in human schwannoma. Cancer Res 2008; 68: 5236-5245.
13. Rong R, Tang X, Gutmann DH, Ye K. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci USA 2004; 101: 18200-18205.
14. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR. Reexpression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006; 25: 5960-5968.
15. Okada M, Wang Y, Jang SW, Tang X, Neri LM, Ye K. Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of merlin. Cancer Res 2009; 69: 4043-4051.
16. Gutmann DH, Sherman L, Seftor L, Haipek C, Hoang Lu K, Hendrix M. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. Hum Mol Genet 1999; 8: 267-275.
17. Gutmann DH, Haipek CA, Hoang LuK. Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations. J Neurosci Res 1999; 58: 706-716.
18. Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 1997; 15: 2505-2509.
19. Gonzalez-Agosti C, Wiederhold T, Herndon ME, Gusella J, Ramesh V. Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF. J Biol Chem 1999; 274: 34438-34442.
20. Gutmann DH, Geist RT, Xu H, Kim JS, Saporito-Irwin S. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet 1998; 7: 335-345.
21. Meng JJ, Lowrie DJ, Sun H, Dorsey E, Pelton PD, Bashour AM et al. Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin. J Neurosci Res 2000; 62: 491-502.
22. Kissil JL, Johnson KC, Eckman MS, Jacks T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 2002; 277: 10394-10399.
23. Wei BL, Arora VK, Raney A, Kuo LS, Xiao GH, O'Neill E et al. Activation of p21-activated kinase 2 by human immunodeficiency virus type 1 Nef induces merlin phosphorylation. J Virol 2005; 79: 14976-14980.
24. Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002; 277: 883-886.
25. Tang X, Jang SW, Wang X, Liu Z, Bahr SM, Sun SY et al. Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol 2007; 9: 1199-1207.
26. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010; 140: 477-490.
27. Bettermann K, Benesch M, Weis S, Haybaeck J. SUMOylation in carcinogenesis. Cancer Lett 2012; 316: 113-125.
28. Muller S, Hoege C, Pyrowolakis G, Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat Rev 2001; 2: 202-210.
29. Hilgarth RS, Murphy LA, Skaggs HS, Wilkerson DC, Xing H, Sarge KD. Regulation and function of SUMO modification. J Biol Chem 2004; 279: 53899-53902.
30. Wang Y, Dasso M. SUMOylation and deSUMOylation at a glance. J Cell Sci 2009; 122(Pt 23): 4249-4252.
31. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. SUMO-1 modification activates the transcriptional response of p53. EMBO J 1999; 18: 6455-6461.
32. Stamenkovic I, Yu Q. Merlin, a 'magic' linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Peptide Sci 2010; 11: 471-484.
33. Lu J, Zou J, Wu H, Cai L. Compensative shuttling of merlin to phosphorylation on serine 518 in vestibular schwannoma. Laryngoscope 2008; 118: 169-174.
34. Rong R, Surace EI, Haipek CA, Gutmann DH, Ye K. Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene 2004; 23: 8447-8454.
35. Alfthan K, Heiska L, Gronholm M, Renkema GH, Carpen O. Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem 2004; 279: 18559-18566.
36. Mani T, Hennigan RF, Foster LA, Conrady DG, Herr AB, Ip W. FERM domain phosphoinositide binding targets merlin to the membrane and is essential for its growth-suppressive function. Mol Cell Biol 2011; 31: 1983-1996.
37. Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011; 19: 527-540.
38. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 2003; 17: 1090-1100.
39. Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene 2009; 28: 854-865.
40. Maitra S, Kulikauskas RM, Gavilan H, Fehon RG. The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling. Curr Biol 2006; 16: 702-709.
41. Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998; 17: 61-70.
42. Gill G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev 2004; 18: 2046-2059.
43. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 2007; 177: 893-903.
44. Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q. Merlin is a potent inhibitor of glioma growth. Cancer Res 2008; 68: 5733-5742.
45. Bae SH, Jeong JW, Park JA, Kim SH, Bae MK, Choi SJ et al. Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem Biophys Res Commun 2004; 324: 394-400.
46. de Cristofaro T, Mascia A, Pappalardo A, D'Andrea B, Nitsch L, Zannini M. Pax8 protein stability is controlled by sumoylation. J Mol Endocrinol 2009; 42: 35-46.
47. Rajan S, Plant LD, Rabin ML, Butler MH, Goldstein SA. Sumoylation silences the plasma membrane leak K+ channel K2P1. Cell 2005; 121: 37-47.
48. Martin S, Nishimune A, Mellor JR, Henley JM. SUMOylation regulates kainatereceptor-mediated synaptic transmission. Nature 2007; 447: 321-325.
49. Jukam D, Desplan C. Binary regulation of Hippo pathway by Merlin/NF2, Kibra, Lgl, and Melted specifies and maintains postmitotic neuronal fate. Dev Cell 2011; 21: 874-887.
50. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biology 2006; 8: 27-36.
51. Murray LB, Lau YK, Yu Q. Merlin is a negative regulator of human melanoma growth. PloS One 2012; 7: e43295.
52. Kressel M, Schmucker B. Nucleocytoplasmic transfer of the NF2 tumor suppressor protein merlin is regulated by exon 2 and a CRM1-dependent nuclear export signal in exon 15. Hum Mol Genet 2002; 11: 2269-2278.
53. Gascard P, Nunomura W, Lee G, Walensky LD, Krauss SW, Takakuwa Y et al. Deciphering the nuclear import pathway for the cytoskeletal red cell protein 4.1R. Mol Biol Cell 1999; 10: 1783-1798.
54. Muranen T, Gronholm M, Renkema GH, Carpen O. Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin. Oncogene 2005; 24: 1150-1158.
55. Brault E, Gautreau A, Lamarine M, Callebaut I, Thomas G, Goutebroze L. Normal membrane localization and actin association of the NF2 tumor suppressor protein are dependent on folding of its N-terminal domain. J Cell Sci 2001; 114(Pt 10): 1901-1912.
56. Konopacki FA, Jaafari N, Rocca DL, Wilkinson KA, Chamberlain S, Rubin P et al. Agonist-induced PKC phosphorylation regulates GluK2 SUMOylation and kainate receptor endocytosis. Proc Natl Acad Sci USA 2011; 108: 19772-19777.
57. Vanhatupa S, Ungureanu D, Paakkunainen M, Silvennoinen O. MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1. Biochem J 2008; 409: 179-185.
58. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 1998; 2: 233-239.
59. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10: 547-555.
60. Li W, Cooper J, Karajannis MA, Giancotti FG. Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep 2012; 13: 204-215.
61. Sher I, Hanemann CO, Karplus PA, Bretscher A. The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state. Dev Cell 2012; 22: 703-705.
62. Merrill JC, Kagey MH, Melhuish TA, Powers SE, Zerlanko BJ, Wotton D. Inhibition of CtBP1 activity by Akt-mediated phosphorylation. J Mol Biol 2010; 398: 657-671.
63. Yu J, Zhang SS, Saito K, Williams S, Arimura Y, Ma Y et al. PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J 2009; 28: 21-33.